Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Research

Background:

• Schizophrenia is a complex mental disorder requiring effective and safe treatment options.
• Lurasidone is an atypical antipsychotic used for schizophrenia treatment.
• Post-marketing surveillance is crucial for evaluating real-world drug safety and effectiveness.

Purpose of the Study:

• To assess the safety and effectiveness of lurasidone in Chinese patients diagnosed with schizophrenia.
• To evaluate adverse events, extrapyramidal symptoms, and weight changes associated with lurasidone use.
• To determine the efficacy of lurasidone in improving psychiatric symptoms as measured by the Brief Psychiatric Rating Scale (BPRS).

Main Methods:

• A 12-week, multicenter, prospective, open-label, single-arm study was conducted in Mainland China.
• The study included adult and adolescent schizophrenia patients initiating lurasidone treatment.
• Safety was monitored through adverse events (AEs) and adverse drug reactions (ADRs), including extrapyramidal symptoms (EPS) and weight gain. Effectiveness was assessed using the BPRS.

Main Results:

• A total of 3170 patients were included in the Full Analysis Set.
• Adverse drug reactions (ADRs) were reported in 7.9% of patients, with extrapyramidal symptoms (EPS) being the most common (3.2%).
• Significant improvements in BPRS scores were observed across all assessed domains (total score, anxiety-depression, anergia, thought disturbance, activation, hostility-suspiciousness) from baseline to week 12 (P < 0.05).

Conclusions:

• Lurasidone demonstrated a favorable safety profile in a real-world setting among Chinese schizophrenia patients.
• The study confirmed the significant clinical effectiveness of lurasidone in improving psychiatric symptoms in both adult and adolescent populations.
• These findings support the use of lurasidone across diverse patient groups with schizophrenia in China.